Company intelligence / Profile preview

ForSight VISION3

Menlo Park, California, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

ForSight VISION3 was formed to develop innovative ophthalmic technologies aimed at improving vision and quality of life for visually impaired patients. The company received $6 million in Series A funding in early 2008 from leading venture capital firms. No clinical results or product launches have been publicly reported as of the latest available data.

Therapeutic areas: Ophthalmology
Modalities: Device (ophthalmic medical devices)
Industry: Therapeutic Medical Devices

Partnerships

Morgenthaler Ventures (investor with board seat)Split Rock Partners (investor with board seat)Versant Ventures (investor with board seat)

Beyond the preview

Go deeper on ForSight VISION3.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ForSight VISION3.

Explore the full profile